Telix Pharmaceuticals Limited Stock Performance
| TLX Stock | 7.08 0.02 0.28% |
The entity has a beta of 0.24, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Telix Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Telix Pharmaceuticals is expected to be smaller as well. At this point, Telix Pharmaceuticals has a negative expected return of -0.45%. Please make sure to validate Telix Pharmaceuticals' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if Telix Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Telix Pharmaceuticals Limited has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's essential indicators remain fairly strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 2.26 | Five Day Return 2.99 | Year To Date Return (4.99) | Ten Year Return (52.21) | All Time Return (52.21) |
1 | TLX DEADLINE ALERT ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important January 9 Deadline in Sec... | 01/02/2026 |
2 | Telix Pharmaceuticals Reaches New 12-Month Low Heres What Happened | 01/08/2026 |
3 | Illuccix Regulatory Progress Positions Telix Pharmaceuticals Across ASX 200 Landscape | 01/20/2026 |
4 | ASX Stocks Possibly Trading Below Their Fair Value Estimates In January 2026 | 01/21/2026 |
5 | 3 ASX 200 shares I would buy before February | 01/22/2026 |
6 | Assessing Telix Pharmaceuticals Valuation After Key China And US Prostate Cancer Milestones | 01/26/2026 |
7 | ASX 200 Focus Telix Momentum Shapes Market Outlook | 01/27/2026 |
8 | Down 60, is there a once-in-a-decade opportunity in this ASX 200 stock | 01/28/2026 |
9 | Will Telix shares drop below 10 | 02/03/2026 |
10 | ASX 200 Watchlist What Rising Market Bets Reveal This Week | 02/09/2026 |
| Begin Period Cash Flow | 123.2 M | |
| Total Cashflows From Investing Activities | -135.2 M |
Telix Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 951.00 in Telix Pharmaceuticals Limited on November 13, 2025 and sell it today you would lose (243.00) from holding Telix Pharmaceuticals Limited or give up 25.55% of portfolio value over 90 days. Telix Pharmaceuticals Limited is generating negative expected returns assuming volatility of 2.8878% on return distribution over 90 days investment horizon. In other words, 25% of stocks are less volatile than Telix, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Telix Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Telix Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 7.08 | 90 days | 7.08 | about 91.24 |
Based on a normal probability distribution, the odds of Telix Pharmaceuticals to move above the current price in 90 days from now is about 91.24 (This Telix Pharmaceuticals Limited probability density function shows the probability of Telix Stock to fall within a particular range of prices over 90 days) .
Telix Pharmaceuticals Price Density |
| Price |
Predictive Modules for Telix Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Telix Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Telix Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Telix Pharmaceuticals is not an exception. The market had few large corrections towards the Telix Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Telix Pharmaceuticals Limited, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Telix Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.55 | |
β | Beta against Dow Jones | 0.24 | |
σ | Overall volatility | 1.04 | |
Ir | Information ratio | -0.21 |
Telix Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Telix Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Telix Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Telix Pharmaceuticals generated a negative expected return over the last 90 days | |
| Telix Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from kalkinemedia.com: ASX 200 Watchlist What Rising Market Bets Reveal This Week |
Telix Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Telix Stock often depends not only on the future outlook of the current and potential Telix Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Telix Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 345.2 M | |
| Cash And Short Term Investments | 710.3 M |
Telix Pharmaceuticals Fundamentals Growth
Telix Stock prices reflect investors' perceptions of the future prospects and financial health of Telix Pharmaceuticals, and Telix Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Telix Stock performance.
| Return On Equity | 0.0314 | ||||
| Return On Asset | 0.0208 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | (0) % | ||||
| Current Valuation | 2.53 B | ||||
| Shares Outstanding | 334.72 M | ||||
| Price To Book | 5.62 X | ||||
| Price To Sales | 3.57 X | ||||
| Revenue | 783.21 M | ||||
| Gross Profit | 358.28 M | ||||
| EBITDA | 98.23 M | ||||
| Net Income | 49.92 M | ||||
| Total Debt | 581.45 M | ||||
| Book Value Per Share | 1.25 X | ||||
| Cash Flow From Operations | 43.03 M | ||||
| Earnings Per Share | 0.02 X | ||||
| Market Capitalization | 3.28 B | ||||
| Total Asset | 1.52 B | ||||
| Retained Earnings | (212.96 M) | ||||
| Working Capital | 587.65 M | ||||
About Telix Pharmaceuticals Performance
Evaluating Telix Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Telix Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Telix Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 58.53 | 55.61 | |
| Return On Tangible Assets | 0.05 | 0.05 | |
| Return On Capital Employed | 0.06 | 0.07 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | 0.10 | 0.11 |
Things to note about Telix Pharmaceuticals performance evaluation
Checking the ongoing alerts about Telix Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Telix Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Telix Pharmaceuticals generated a negative expected return over the last 90 days | |
| Telix Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from kalkinemedia.com: ASX 200 Watchlist What Rising Market Bets Reveal This Week |
- Analyzing Telix Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Telix Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Telix Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Telix Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Telix Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Telix Pharmaceuticals' stock. These opinions can provide insight into Telix Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.